Chemotherapy cycles in study group (n=182) | Chemotherapy cycles in control group (n=483) | P value | Chemotherapy cycles of long-acting G-CSF utilisation (n=258) | Chemotherapy cycles of only short-acting G-CSF utilisation (n=347) | P value | |
Short-acting G-CSF utilisation, n (%) | 79 (43.4%) | 230 (54.4%) | 0.013 | 95 (36.8%) | 214 (61.7%) | <0.001 |
Doses, mean±SD | 1.0±1.7 | 2.0±2.6 | <0.001 | 0.8±1.6 | 2.3±2.7 | <0.001 |
Clinical visits, mean±SD | ||||||
Visits to ER | 0.3±0.9 | 1.0±1.8 | <0.001 | 0.5±1.2 | 1.0±1.8 | <0.001 |
Visits to outpatient clinics | 1.8±1.3 | 2.5±1.4 | <0.001 | 2.0±1.3 | 2.5±1.5 | <0.001 |
All visits | 2.1±1.7 | 3.5±2.5 | <0.001 | 2.5±1.9 | 3.5±2.6 | <0.001 |
CBC times, mean±SD | 5.0±1.9 | 5.3±2.1 | 0.192 | 4.9±2.0 | 5.4±2.1 | 0.003 |
FN, n (%) | 5 (2.7%) | 33 (7.8%) | 0.019 | 7 (2.7%) | 31 (8.9%) | 0.002 |
Lasting duration (day), mean±SD | 1.8±0.8 (n=5) | 1.3±0.6 (n=33) | 0.289 | 1.7±0.8 (n=7) | 1.3±0.6 (n=31) | 0.171 |
Admission for FN, n (%) | 3/5 (60%) | 22/33 (66.7%) | 0.567 | 4/7 (57.1%) | 21/31 (67.7%) | 0.451 |
Antibiotics for FN, n (%) | 5/5 (100.0%) | 27/33 (81.8%) | 0.401 | 7/7 (100.0%) | 25/31 (0.267%) | 0.267 |
Myelosuppression, n (%) | ||||||
All | 79 (43.4%) | 292 (69.0%) | <0.001 | 113 (43.8%) | 258 (74.4%) | <0.001 |
Grade 3/4 | 36 (19.8%) | 174 (41.1%) | <0.001 | 47 (18.2%) | 163 (47.0%) | <0.001 |
Grade 4 | 12 (6.6%) | 73 (17.3%) | <0.001 | 15 (5.8%) | 70 (20.2%) | <0.001 |
G-CSF-associated pain, n (%) | 60/182 (33.0%) | 200/423 (47.3%) | 0.001 | 96/223 (43.0%) | 164/221 (74.2%) | <0.001 |
VAS, mean±SD | 1.8±2.6 | 1.4±2.0 | 0.214 | 1.7±2.4 | 1.4±2.0 | 0.150 |
Skin rash, n (%) | 4/182 (2.2%) | 6/421 (1.4%) | 0.355 | 5/258 (1.9%) | 5/347 (1.4%) | 0.434 |
Delay of chemotherapy, n (%) | 17 (9.3%) | 50 (11.8%) | 0.373 | 23 (8.9%) | 44 (12.7%) | 0.144 |
Delayed days, mean±SD | 0.5±2.2 | 0.5±1.9 | 0.930 | 0.4±2.0 | 0.5±1.9 | 0.162 |
CBC, complete blood count; ER, emergency room; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; VAS, visual analogue scale.